1841. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
作者: Gilmar Reis.;Eduardo Augusto Dos Santos Moreira Silva.;Daniela Carla Medeiros Silva.;Lehana Thabane.;Vitoria Helena de Souza Campos.;Thiago Santiago Ferreira.;Castilho Vitor Quirino Dos Santos.;Ana Maria Ribeiro Nogueira.;Ana Paula Figueiredo Guimaraes Almeida.;Leonardo Cançado Monteiro Savassi.;Adhemar Dias de Figueiredo Neto.;Carina Bitarães.;Aline Cruz Milagres.;Eduardo Diniz Callegari.;Maria Izabel Campos Simplicio.;Luciene Barra Ribeiro.;Rosemary Oliveira.;Ofir Harari.;Lindsay A Wilson.;Jamie I Forrest.;Hinda Ruton.;Sheila Sprague.;Paula McKay.;Christina M Guo.;Gordon H Guyatt.;Craig R Rayner.;David R Boulware.;Nicole Ezer.;Todd C Lee.;Emily Gibson McDonald.;Mona Bafadhel.;Christopher Butler.;Josue Rodrigues Silva.;Mark Dybul.;Edward J Mills.; .
来源: Ann Intern Med. 2023年176卷5期667-675页
Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19.
1842. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
作者: Teresa H Evering.;Kara W Chew.;Mark J Giganti.;Carlee Moser.;Mauricio Pinilla.;David Alain Wohl.;Judith S Currier.;Joseph J Eron.;Arzhang Cyrus Javan.;Rachel Bender Ignacio.;David Margolis.;Qing Zhu.;Ji Ma.;Lijie Zhong.;Li Yan.;Ulises D'Andrea Nores.;Keila Hoover.;Bharat Mocherla.;Manish C Choudhary.;Rinki Deo.;Justin Ritz.;William A Fischer.;Courtney V Fletcher.;Jonathan Z Li.;Michael D Hughes.;Davey Smith.;Eric S Daar.; .
来源: Ann Intern Med. 2023年176卷5期658-666页
Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life.
1844. How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
作者: Gerald W Smetana.;C Christopher Smith.;Ajay Singla.;Howard Libman.
来源: Ann Intern Med. 2023年176卷4期545-555页
Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) are common in older patients assigned male sex at birth, regardless of gender identity, and treatment of these symptoms is therefore common in primary care practice. In 2021, the American Urological Association published guidelines for management of BPH. They recommend using a standardized scoring system such as the International Prostate Symptom Score to help establish a diagnosis and to monitor the efficacy of interventions, α-blockers as the first-choice pharmacotherapy option, and 5α-reductase inhibitors for patients with prostate size estimated to be at least 30 cc. Tadalafil is another option regardless of erectile dysfunction. Combination therapies with α-blockers and 5α-reductase inhibitors, anticholinergic agents, or β3-agonists are effective options. A surgical referral is warranted if the BPH results in chronic kidney disease, refractory urinary retention, or recurrent urinary tract infections; if there is concern for bladder or prostate cancer; or if symptoms do not respond to medical therapy. In this article, a general internal medicine physician and a urologist discuss the treatment options and how they would apply their recommendations to a patient who wishes to learn more about his options.
1845. Periprocedural Anticoagulation.
Management of patients taking anticoagulants around the time of a procedure is a common and complex clinical scenario. Providing evidence-based care requires estimation of risk for thrombosis and bleeding, knowledge of commonly used medications, multidisciplinary communication and collaboration, and patient engagement and education. This review provides a standardized, evidence-based approach to periprocedural management of anticoagulation, based on current evidence and expert clinical guidelines.
1846. Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism.
作者: Carolyn D Seib.;Calyani Ganesan.;Adam Furst.;Alan C Pao.;Glenn M Chertow.;John T Leppert.;Insoo Suh.;Maria E Montez-Rath.;Alex H S Harris.;Amber W Trickey.;Electron Kebebew.;Manjula Kurella Tamura.
来源: Ann Intern Med. 2023年176卷5期624-631页
Multidisciplinary guidelines recommend parathyroidectomy to slow the progression of chronic kidney disease in patients with primary hyperparathyroidism (PHPT) and an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2. Limited data address the effect of parathyroidectomy on long-term kidney function.
1847. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
作者: Kevin E Kip.;Erin K McCreary.;Kevin Collins.;Tami E Minnier.;Graham M Snyder.;William Garrard.;Jeffrey C McKibben.;Donald M Yealy.;Christopher W Seymour.;David T Huang.;J Ryan Bariola.;Mark Schmidhofer.;Richard J Wadas.;Derek C Angus.;Paula L Kip.;Oscar C Marroquin.
来源: Ann Intern Med. 2023年176卷4期496-504页
Treatment guidelines and U.S. Food and Drug Administration emergency use authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients with mild to moderate COVID-19 changed frequently as different SARS-CoV-2 variants emerged.
1848. After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancers.
Hugosson J, Månsson M, Wallström J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126-37. 36477032.
1849. In older adults with hypertension, chlorthalidone vs. hydrochlorothiazide did not reduce major CV events or deaths at 2.4 y.
Diuretic Comparison Project Writing Group; Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022;387:2401-10. 36516076.
1850. After PCI and 6 to 18 mo of DAPT, clopidogrel reduced a composite of clinical events vs. aspirin at 6 y.
Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: The HOST-EXAM extended study. Circulation. 2023;147:108-17. 36342475.
1851. In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency.
Guo X, Zhang D, Pang H, et al. Safety of withholding perioperative hydrocortisone for patients with pituitary adenomas with an intact hypothalamus-pituitary-adrenal axis: a randomized clinical trial. JAMA Netw Open. 2022;5:e2242221. 36383383.
1852. In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo.
Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.
1854. In BPPV, canalith repositioning maneuver increased symptom resolution vs. vestibular suppressants.
Sharif S, Khoujah D, Greer A, et al. Vestibular suppressants for benign paroxysmal positional vertigo: a systematic review and meta-analysis of randomized controlled trials. Acad Emerg Med. 2022. [Epub ahead of print.] 36268806.
1855. In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding.
Khairani CD, Bejjani A, Piazza G, et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol. 2023;81:16-30. 36328154.
1856. In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d.
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.
1857. In older patients receiving aspirin, H pylori eradication reduced hospitalization or death due to peptic ulcer bleeding at 2.5 y.
Hawkey C, Avery A, Coupland CAC, et al; HEAT trialists. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022;400:1597-1606. 36335970.
1858. In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death.
Kalra PR, Cleland JG, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-209. 36347265.
1859. Facilitating Shared Decision Making Among Black Patients at Risk for Sudden Cardiac Arrest : A Randomized Clinical Trial.
作者: Kevin L Thomas.;Sana M Al-Khatib.;Andrzej S Kosinski.;Samuel F Sears.;Nancy M Allen LaPointe.;Larry R Jackson.;Daniel D Matlock.;Daniel Haithcock.;B Judson Colley.;David S Hirsh.;Eric D Peterson.
来源: Ann Intern Med. 2023年176卷5期615-623页
Racial disparities in implantable cardioverter-defibrillator (ICD) implantation are multifactorial and are partly explained by higher refusal rates.
1860. Incremental Health Care Costs of Self-Reported Functional Impairments and Phenotypic Frailty in Community-Dwelling Older Adults : A Prospective Cohort Study.
作者: Kristine E Ensrud.;John T Schousboe.;Allyson M Kats.;Brent C Taylor.;Cynthia M Boyd.;Lisa Langsetmo.
来源: Ann Intern Med. 2023年176卷4期463-471页
Health care systems need better strategies to identify older adults at risk for costly care to select target populations for interventions to reduce health care burden.
|